379 related articles for article (PubMed ID: 16326107)
1. Alterations in degradative pathways and protein aggregation in a neuropathy model based on PMP22 overexpression.
Fortun J; Go JC; Li J; Amici SA; Dunn WA; Notterpek L
Neurobiol Dis; 2006 Apr; 22(1):153-64. PubMed ID: 16326107
[TBL] [Abstract][Full Text] [Related]
2. Impaired proteasome activity and accumulation of ubiquitinated substrates in a hereditary neuropathy model.
Fortun J; Li J; Go J; Fenstermaker A; Fletcher BS; Notterpek L
J Neurochem; 2005 Mar; 92(6):1531-41. PubMed ID: 15748170
[TBL] [Abstract][Full Text] [Related]
3. The formation of peripheral myelin protein 22 aggregates is hindered by the enhancement of autophagy and expression of cytoplasmic chaperones.
Fortun J; Verrier JD; Go JC; Madorsky I; Dunn WA; Notterpek L
Neurobiol Dis; 2007 Feb; 25(2):252-65. PubMed ID: 17174099
[TBL] [Abstract][Full Text] [Related]
4. The alpha-chemokine CXCL14 is up-regulated in the sciatic nerve of a mouse model of Charcot-Marie-Tooth disease type 1A and alters myelin gene expression in cultured Schwann cells.
Barbaria EM; Kohl B; Buhren BA; Hasenpusch-Theil K; Kruse F; Küry P; Martini R; Müller HW
Neurobiol Dis; 2009 Mar; 33(3):448-58. PubMed ID: 19111616
[TBL] [Abstract][Full Text] [Related]
5. Molecular alterations resulting from frameshift mutations in peripheral myelin protein 22: implications for neuropathy severity.
Johnson JS; Roux KJ; Fletcher BS; Fortun J; Notterpek L
J Neurosci Res; 2005 Dec; 82(6):743-52. PubMed ID: 16273544
[TBL] [Abstract][Full Text] [Related]
6. Proliferation of Schwann cells and regulation of cyclin D1 expression in an animal model of Charcot-Marie-Tooth disease type 1A.
Atanasoski S; Scherer SS; Nave KA; Suter U
J Neurosci Res; 2002 Feb; 67(4):443-9. PubMed ID: 11835311
[TBL] [Abstract][Full Text] [Related]
7. Peripheral myelin protein-22 expression in Charcot-Marie-Tooth disease type 1a sural nerve biopsies.
Hanemann CO; Stoll G; D'Urso D; Fricke W; Martin JJ; Van Broeckhoven C; Mancardi GL; Bartke I; Müller HW
J Neurosci Res; 1994 Apr; 37(5):654-9. PubMed ID: 8028042
[TBL] [Abstract][Full Text] [Related]
8. Biochemical characterization of protein quality control mechanisms during disease progression in the C22 mouse model of CMT1A.
Chittoor VG; Sooyeon L; Rangaraju S; Nicks JR; Schmidt JT; Madorsky I; Narvaez DC; Notterpek L
ASN Neuro; 2013 Dec; 5(5):e00128. PubMed ID: 24175617
[TBL] [Abstract][Full Text] [Related]
9. Identification of the regulatory region of the peripheral myelin protein 22 (PMP22) gene that directs temporal and spatial expression in development and regeneration of peripheral nerves.
Maier M; Berger P; Nave KA; Suter U
Mol Cell Neurosci; 2002 May; 20(1):93-109. PubMed ID: 12056842
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory demyelination in a patient with CMT1A.
Vital A; Vital C; Lagueny A; Ferrer X; Ribière-Bachelier C; Latour P; Petry KG
Muscle Nerve; 2003 Sep; 28(3):373-6. PubMed ID: 12929199
[TBL] [Abstract][Full Text] [Related]
11. Many facets of the peripheral myelin protein PMP22 in myelination and disease.
Naef R; Suter U
Microsc Res Tech; 1998 Jun; 41(5):359-71. PubMed ID: 9672419
[TBL] [Abstract][Full Text] [Related]
12. Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice.
Adlkofer K; Martini R; Aguzzi A; Zielasek J; Toyka KV; Suter U
Nat Genet; 1995 Nov; 11(3):274-80. PubMed ID: 7581450
[TBL] [Abstract][Full Text] [Related]
13. Impairment of PMP22 transgenic Schwann cells differentiation in culture: implications for Charcot-Marie-Tooth type 1A disease.
Nobbio L; Vigo T; Abbruzzese M; Levi G; Brancolini C; Mantero S; Grandis M; Benedetti L; Mancardi G; Schenone A
Neurobiol Dis; 2004 Jun; 16(1):263-73. PubMed ID: 15207283
[TBL] [Abstract][Full Text] [Related]
14. Myelin and axon pathology in a long-term study of PMP22-overexpressing mice.
Verhamme C; King RH; ten Asbroek AL; Muddle JR; Nourallah M; Wolterman R; Baas F; van Schaik IN
J Neuropathol Exp Neurol; 2011 May; 70(5):386-98. PubMed ID: 21487305
[TBL] [Abstract][Full Text] [Related]
15. Aggresome formation in neuropathy models based on peripheral myelin protein 22 mutations.
Ryan MC; Shooter EM; Notterpek L
Neurobiol Dis; 2002 Jul; 10(2):109-18. PubMed ID: 12127149
[TBL] [Abstract][Full Text] [Related]
16. Distinct disease mechanisms in peripheral neuropathies due to altered peripheral myelin protein 22 gene dosage or a Pmp22 point mutation.
Giambonini-Brugnoli G; Buchstaller J; Sommer L; Suter U; Mantei N
Neurobiol Dis; 2005 Apr; 18(3):656-68. PubMed ID: 15755691
[TBL] [Abstract][Full Text] [Related]
17. Distal axonopathy in peripheral nerves of PMP22-mutant mice.
Sancho S; Magyar JP; Aguzzi A; Suter1 U
Brain; 1999 Aug; 122 ( Pt 8)():1563-77. PubMed ID: 10430839
[TBL] [Abstract][Full Text] [Related]
18. PMP22 accumulation in aggresomes: implications for CMT1A pathology.
Notterpek L; Ryan MC; Tobler AR; Shooter EM
Neurobiol Dis; 1999 Oct; 6(5):450-60. PubMed ID: 10527811
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A).
Sereda MW; Meyer zu Hörste G; Suter U; Uzma N; Nave KA
Nat Med; 2003 Dec; 9(12):1533-7. PubMed ID: 14608378
[TBL] [Abstract][Full Text] [Related]
20. Polytherapy with a combination of three repurposed drugs (PXT3003) down-regulates Pmp22 over-expression and improves myelination, axonal and functional parameters in models of CMT1A neuropathy.
Chumakov I; Milet A; Cholet N; Primas G; Boucard A; Pereira Y; Graudens E; Mandel J; Laffaire J; Foucquier J; Glibert F; Bertrand V; Nave KA; Sereda MW; Vial E; Guedj M; Hajj R; Nabirotchkin S; Cohen D
Orphanet J Rare Dis; 2014 Dec; 9():201. PubMed ID: 25491744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
